Growth Metrics

Innoviva (INVA) EBT Margin (2011 - 2026)

Innoviva posted quarterly EBT Margin of 239.36% for Q1 2026, up 28290.0% year-on-year from N/an in Q1 2025, and up 118.79% on a QoQ basis from 1274.01% in Q4 2025.

Innoviva (INVA) has 16 years of EBT Margin data on file, last reported at 239.36% in Q1 2026.

  • For the quarter ending Q1 2026, EBT Margin rose 28290.0% year-over-year to 239.36%; the trailing twelve-month figure through Mar 2026 stood at 127.34% (up 15655.0% YoY), and the FY2025 full-year result was 79.51%, up 6910.0% from the prior year.
  • EBT Margin for Q1 2026 stood at 239.36%, up from 1274.01% in the prior quarter.
  • Across five years, EBT Margin topped out at 22032.62% in Q3 2022 and bottomed at 1274.01% in Q4 2025.
  • The 5-year median for EBT Margin is 90.74% (2025), against an average of 2005.03%.
  • The widest annual swing landed in 2022, when EBT Margin soared 2190675 bps; it then plunged 2190482 bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 982.68% in 2022, then soared by 56 bps to 430.5% in 2023, then sank by 98 bps to 853.36% in 2024, then plunged by 49 bps to 1274.01% in 2025, then soared by 119 bps to 239.36% in 2026.
  • The last three EBT Margin figures came in at 239.36% (Q1 2026), 1274.01% (Q4 2025), and 90.74% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.40%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 41.95%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 23.05%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 18.99%
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn 239.36%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 239.36%
Dec 31, 2025 -1,274.01%
Sep 30, 2025 90.74%
Jun 30, 2025 72.39%
Mar 31, 2025 -43.54%
Dec 31, 2024 -853.36%
Sep 30, 2024 7.65%
Jun 30, 2024 -39.32%
Mar 31, 2024 4,671.22%
Dec 31, 2023 -430.50%
Sep 30, 2023 127.79%
Jun 30, 2023 592.35%
Mar 31, 2023 5,168.34%
Dec 31, 2022 -982.68%
Sep 30, 2022 22,032.62%
Jun 30, 2022 1,088.42%
Mar 31, 2022 3,617.96%
Dec 31, 2021 -611.53%
Sep 30, 2021 125.87%
Jun 30, 2021 11,659.16%
Mar 31, 2021 12,141.74%
Dec 31, 2020 18,007.54%
Sep 30, 2020 56.92%
Jun 30, 2020 149.62%
Mar 31, 2020 120.60%
Dec 31, 2019 92.49%
Sep 30, 2019 87.61%
Jun 30, 2019 88.12%
Mar 31, 2019 87.94%
Dec 31, 2018 91.59%
Sep 30, 2018 81.33%
Jun 30, 2018 84.39%
Mar 31, 2018 57.90%
Dec 31, 2017 43.60%
Sep 30, 2017 69.96%
Jun 30, 2017 61.36%
Mar 31, 2017 41.48%
Dec 31, 2016 56.94%
Sep 30, 2016 44.96%
Jun 30, 2016 39.66%
Mar 31, 2016 18.48%
Dec 31, 2015 18.83%
Sep 30, 2015 -33.80%
Jun 30, 2015 -73.30%
Mar 31, 2015 -154.68%
Dec 31, 2014 -218.76%
Sep 30, 2014 -2,157.06%
Jun 30, 2014 -2,127.73%
Mar 31, 2014 -2,074.62%
Dec 31, 2013 -603.80%
Sep 30, 2013 -2,278.07%
Jun 30, 2013 -116.57%
Mar 31, 2013 -2,718.46%
Dec 31, 2012 34.96%
Sep 30, 2012 -2,426.01%
Jun 30, 2012 -7,097.51%
Mar 31, 2012 67.24%
Dec 31, 2011 -690.17%
Sep 30, 2011 -476.22%
Jun 30, 2011 -392.00%
Mar 31, 2011 -360.32%